GlaxoSmithKline
- Country
- π¬π§United Kingdom
- Ownership
- Public
- Established
- 1929-01-01
- Employees
- 70.2K
- Market Cap
- $90B
- Website
- http://www.gsk.com
- Introduction
GSK Plc is a healthcare company, which engages in the research, development, and manufacture of pharmaceutical medicines, vaccines, and consumer healthcare products. It operates through the Commercial Operations, and Research and Development segments. The Commercial Operations segment has three product groups of specialty medicines, vaccines, and general medicines. The company was founded in 1715 and is headquartered in Middlesex, the United Kingdom.
Intravenous Mepolizumab In Subjects With Hypereosinophilic Syndromes (HES)
- Conditions
- HypereosinophiliaHypereosinophilic Syndrome
- First Posted Date
- 2004-07-09
- Last Posted Date
- 2020-05-05
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 86
- Registration Number
- NCT00086658
- Locations
- π¨π
GSK Investigational Site, Bern, Switzerland
Study Of An FDA-approved Drug As Additional Therapy In Patients With Schizophrenia
- Conditions
- Schizophrenia
- First Posted Date
- 2004-07-08
- Last Posted Date
- 2016-10-07
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 209
- Registration Number
- NCT00086593
- Locations
- π¬π§
GSK Investigational Site, Hull, United Kingdom
KALETRA Or LEXIVA With Ritonavir Combined With EPIVIR And Abacavir In Naive Subjects Over 48 Weeks
- Conditions
- HIV InfectionInfection, Human Immunodeficiency Virus
- First Posted Date
- 2004-06-21
- Last Posted Date
- 2011-05-16
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 866
- Registration Number
- NCT00085943
- Locations
- π¨π
GSK Investigational Site, St Gallen, Switzerland
Dose-Escalating Study Of SB-485232 Administered Intravenously Every 28 Days To Adults With Solid Tumors Or Lymphomas
- Conditions
- Solid Tumor CancerLymphoma
- First Posted Date
- 2004-06-18
- Last Posted Date
- 2008-10-13
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 12
- Registration Number
- NCT00085904
- Locations
- πΊπΈ
GSK Investigational Site, Pittsburgh, Pennsylvania, United States
Dose-Escalation Study Of SB-485232 Administered As Daily Subcutaneous Injections In Adults With Solid Tumors
- Conditions
- Solid Tumor Cancer
- First Posted Date
- 2004-06-18
- Last Posted Date
- 2008-10-16
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 25
- Registration Number
- NCT00085878
- Locations
- πΊπΈ
GSK Investigational Site, Philadelphia, Pennsylvania, United States
Ispinesib In Patients With Advanced Or Metastatic Non-Small Cell Lung Cancer
- Conditions
- Non-Small-Cell Lung Cancer
- First Posted Date
- 2004-06-17
- Last Posted Date
- 2010-10-04
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 70
- Registration Number
- NCT00085813
- Locations
- π¬π§
GSK Investigational Site, Sutton, Surrey, United Kingdom
A Study Comparing The Safety, Tolerability and Efficacy of Trizivir VS Combivir & Atazanavir In Subjects With HIV
- Conditions
- Infection, Human Immunodeficiency Virus IHIV Infection
- First Posted Date
- 2004-05-10
- Last Posted Date
- 2017-05-24
- Lead Sponsor
- GlaxoSmithKline
- Registration Number
- NCT00082394
- Locations
- π²π½
GSK Investigational Site, Monterrey, Nuevo LeΓ³n, Mexico
506U78 in Treating Patients With Chronic Lymphocytic Leukemia That Has Not Responded to Fludarabine or Alkylating Agents
- Conditions
- Leukemia
- First Posted Date
- 2004-03-31
- Last Posted Date
- 2013-07-18
- Lead Sponsor
- GlaxoSmithKline
- Registration Number
- NCT00003635
- Locations
- πΊπΈ
Arizona Cancer Center, Tucson, Arizona, United States
πΊπΈJohns Hopkins Oncology Center, Baltimore, Maryland, United States
πΊπΈClinical Studies, Ltd., Denver, Colorado, United States
Vinorelbine in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer
- Conditions
- Lung Cancer
- First Posted Date
- 2004-03-24
- Last Posted Date
- 2014-01-06
- Lead Sponsor
- GlaxoSmithKline
- Registration Number
- NCT00005865
- Locations
- πΊπΈ
NorthBay Healthcare System, Fairfield, California, United States
πΊπΈUniversity of Chicago Cancer Research Center, Chicago, Illinois, United States
πΊπΈIreland Cancer Center, Cleveland, Ohio, United States
A Clinical Research Study For The Suppression And Treatment Of Genital Herpes Infection In HIV-Infected Persons
- First Posted Date
- 2004-03-19
- Last Posted Date
- 2020-11-24
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 7
- Registration Number
- NCT00079911
- Locations
- ππ°
GSK Investigational Site, Kowloon Bay, Hong Kong